In this podcast episode, we take on the challenge of treatment-resistant depression and its therapeutic options. Dr. Philip Cowen (University of Oxford) provided insights for this clinical conundrum with a simple algorithm.Read More
Dr. Mark Zimmerman, professor of psychiatry and human behavior at Brown University, speaks about depression efficacy trials and their clinical implications.
This interview is part of a series covering the 2018 ASCP Annual Meeting.
Dr. Robin Carthart-Harris, Head of the Psychedelic Research Group at Imperial College London, speaks about the use of psilocybin for treatment-resistant depression. This interview is part of a series covering the 2018 ASCP Annual Meeting.Read More
Prof. Philip Cowen Professor of Psychopharmacology Department of Psychiatry University of Oxford, UK This presentation compares advantages and disadvantages of using quetiapine vs. aripiprazole as augmentation for treatment-resistant depression. It also addresses the common question of when to augment (antidepressant + SGA) vs. when to switch (prescribing a different antidepressant). Combination and Augmentation: Clarifying Concepts…Read More
Prof. Philip Cowen Professor of Psychopharmacology Department of Psychiatry University of Oxford, UK This presentation summarizes recent findings on the role of inflammation in depression. A study suggests patients with elevated levels of inflammatory markers (C-reactive protein) have a differential response to a specific antidepressant. The efficacy of celecoxib and infliximab in treatment-resistant depression is…Read More